Plus   Neg

Stock Alert: AnPac Bio-Medical Science Up 16%

Shares of nano-cap company AnPac Bio-Medical Science Co., Ltd. (ANPC) are gaining over 16% on Monday morning after the biotech company announced that its investee company in China received COVID-19 nucleic acid test certification.

ANPC is currently trading at $3.73, up $0.52 or 16.1994%, on the Nasdaq.

AnPac Bio-Medical Science, a biotechnology company with operations in China and the US, said that its investee company in China, Jiangsu AnPac Health Management Co., Ltd., qualified for COVID-19 nucleic acid tests in the first half of 2020 and received certification from the regulatory authority on October 17, 2020 for COVID-19 nucleic acid tests.

Recently, AnPac Bio and Jiangsu AnPac have signed an agreement to develop and qualify new COVID-19 test technologies and products, and carry out evaluations at Jiangsu AnPac's medical lab.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration on Saturday authorized Johnson & Johnson's (JNJ) single-dose COVID-19 vaccine for emergency use. It is the first single-shot COVID-19 vaccine and the third COVID-19 vaccine for emergency use in the U.S. - the other two being Pfizer/BioNTech's BNT162b2 and Moderna's mRNA-1273. The U.S. Food and Drug Administration said that it will rapidly work toward finalization and issuance of an emergency use authorization of Johnson & Johnson's (JNJ) single-shot COVID-19 vaccine candidate. Billionaire Warren Buffett's Berkshire Hathaway Inc. (BRK.A, BRK.B) reported that its fourth-quarter net earnings attributable to shareholders rose 23 percent to $35.84 billion from last year's $29.16 billion, with earnings per share improving to $23,015 per Class A share from $17,909 per Class A share in the prior year.
Follow RTT